



Deutsche Gesellschaft für Nuklearmedizin e.V.

Translational Research in Molecular Imaging and Radionuclid Therapy

August 31 – September 2, 2017

Kinetic Modelling and Quantitative Imaging

Dr. Kuangyu Shi Dept. Nuclear Medicine Technische Universität München



Molecular Imaging







Challenges of Molecular Imaging Quantification















Quantitative Analysis: Dynamic PET & Time-Activity Curve (TAC)







Quantitative Analysis: Pharmacokinetic Modeling







$$c_a \xrightarrow{K_1} c_t \xrightarrow{k_2}$$

- Compartment: a theoretical volume for tracer
- Instant homogeneous distribution within entire compartment
- Steady-state: constant physiological processes & molecular interactions
- □ Transport between compartments: pure diffusion
- □ Linear interconnections among compartments











Radioactive decay

$$\frac{dc}{dt} = -\lambda c$$

Compartmental representation



















Physiological process

- Free ligand in plasma
- Permeation through endothelium
- Free ligand in tissue
- A fraction binds to receptor
- A fraction dissociates again
- Diffusion back to plasma

Model

- Physical / Chemical states
 - => Compartments
 - well mixed homogenous material
 - Not physical volume



Interstitial+intracellular transport

+metabolism







- □ Fixed number of compartments
- □ Transport between compartments: pure diffusion
- Linear interconnections among compartments
- □ First-order process: transfer proportional concentration
- Constant-coefficient, ODE
- Curve fitting of TAC







- \Box Arterial concentration $C_p(t)$: measured
- Concentration in tissue compartments:
 - $> C_1(t)$: free tracer
 - C₂(t): specifically bound tracer
- Concentration change:









C.





$$C_{tissue}(t) = C_1(t) + C_2(t)$$



Tissue

$$C_{1}(t) = IRF_{1} (K_{1}, k_{2}, k_{3}, k_{4}, t) \otimes C_{p}(t)$$

$$C_{2}(t) = IRF_{2} (K_{1}, k_{2}, k_{3}, k_{4}, t) \otimes C_{p}(t)$$

$$IRF_{1} (K_{1}, k_{2}, k_{3}, k_{4}, t) = \frac{K_{1}}{(\alpha_{2} - \alpha_{1})} [(k_{4} - \alpha_{1})e^{-\alpha_{1}t} + (\alpha_{2} - k_{4})e^{-\alpha_{2}t}]$$

$$IRF_{2} (K_{1}, k_{2}, k_{3}, k_{4}, t) = \frac{K_{1}k_{3}}{(\alpha_{2} - \alpha_{1})} [e^{-\alpha_{1}t} + e^{-\alpha_{2}t}]$$

$$\alpha_{1} = \frac{(k_{2} + k_{3} + k_{4}) - \sqrt{(k_{2} + k_{3} + k_{4})^{2} - 4k_{2}k_{4}}}{2} \quad \alpha_{2} = \frac{(k_{2} + k_{3} + k_{4}) + \sqrt{(k_{2} + k_{3} + k_{4})^{2} - 4k_{2}k_{4}}}{2}$$



Deutsche Gesellschaft für Nuklearmedizin e.V.

Summer School 2017, 31. August - 2. September 2017



□ Given K_1 , k_2 , k_3 , k_4 and $C_p(t)$ □ Calculate $C_{model}(t)$





Deutsche Gesellschaft für Nuklearmedizin e.V.

Summer School 2017, 31. August - 2. September 2017

PMOD



□ Criteria of difference between $C_{\text{measure}}(t)$ and $C_{\text{model}}(t)$: χ^2 □ Optimization algorithm: modify K_1 , k_2 , k_3 , k_4 to minimize χ^2





Deutsche Gesellschaft für Nuklearmedizin e.V.

Summer School 2017, 31. August - 2. September 2017



Compartmental Model





Local Minima of Nonlinear Fitting

- a) & b): parametric images (k1 & k4) using direct voxel-wise modeling (PMOD) for a slice of Patient #1;
- □ c): an example TAC and the three resulting modeling curves fitted using three different sets of initial values:
 - Model1: χ² =0.723; k1=0.10, k2=0.12, k3=0.01, k4=0, VB=0.14
 - Model2: χ² =0.749; k1=0.81, k2=5.42, k3=0.64, k4=0.11, VB=0.05
 - Model3: χ² =0.754; k1=0.15, k2=0.66, k3=0.63, k4=0.20, VB=0.13





Deutsche Gesellschaft für Nuklearmedizin e.V.

Summer School 2017, 31. August - 2. September 2017



- Assumption: Similar TACs has similar kinetic parameters
- □ Clustering the TACs according to their similarities
- Gradually refining the initial values and fitting boundaries



















Example Application of Pharmacokinetic Modeling



[Kunz et al Neuro Oncol 2011]



UMMER
CHOOLExample Application of PharmacokineticModeling

- 10 Patients: 4 Low Grade (WHO II), 6 High Grade (WHO III &IV)
- Dynamic [¹⁸F]FET for 40 min (Siemens mMR)
- □ OSEM 3D (3 iterations, 21 subsets)
- Tumor delineation on PET + Flair fusion
- □ Image-derived AIF from internal carotid artery (PET + MPRage)





UMMER Example Application of Pharmacokinetic CHOOL Modeling



Patient Grade II

Patient Grade IV



Deutsche Gesellschaft für Nuklearmedizin e.V.

Summer School 2017, 31. August - 2. September 2017

MER Linear Model (Graphical Analysis)

$$C_a \xrightarrow{K_1} C_t \xrightarrow{k_2}$$

Compartment model:

- > Non-linear curve fitting
- Time consuming
- Not enough robust

Differential form => integration form Nonlinear fitting => linear fitting



 $c_t = K_1 e^{-k_2 t} \otimes c_a$









- Compartment model => Graphical model
- Irreversible two compartment model => Patlak Plot
- Reversible two compartment model => Logan Plot









Deutsche Gesellschaft für Nuklearmedizin e.V.

Summer School 2017, 31. August - 2. September 2017



DPET Reconstruction



Detections

4D Tomographic images





• Low SNR:

[Cheng et al. SNM 2012]

→ Indirect parametric image generation:



Spatial Information Temporal Information





• Improve SNR:

 \rightarrow Direct parametric image reconstruction:

[Mattews et al. Phys. Med. Biol. 1997] [Tsoumpas et al. Med. Phys. 2008] [Wang et al. Phys. Med. Biol. 2008]

Time Sinogram

Spatial Information + Temporal Information





[Cheng et al. Phys. Med. Biol. 2014]



FBP + Patlak Model



OSEM + Patlak Model

Indirect Methods



POSEM + Patlak Model

Direct Methods



UMMER Advanced Pharmacokinetic Modeling CHOOL Computing: Multiple Tracer Imaging

Different tracer: different tumor phenotype

- [¹⁸F]FDG: Glucose metabolism
- [¹⁸F]FMISO: Tumor hypoxia
- ▶ [¹⁸F]FLT: Proliferation
- [¹¹C]Acetate: Oxidative metabolism
- Pulmonary lesion (16 malignant tumor, 16 tuberculosis, 23 benign lesions)
 - [¹⁸F]FDG: sensitivity 87.5% specificity 59.0%
 - [¹⁸F]FLT: sensitivity 68.8% specificity 76.9%
- [Tian et al. J Nucl Med 2008]
 - [¹⁸F]FDG+[¹⁸F]FLT: sensitivity 100% specificity 89.7%

Hepatocellular carcinoma (99 HCC, 13 cholangiocellular carcinoma)

- [¹⁸F]FDG: sensitivity 60.9%
- [¹¹C]Acetate: sensitivity 75.4%
- [¹⁸F]FDG+[¹¹C]Acetate: sensitivity 82.7%

[Park et al J Nucl Med 2008]

Advanced Pharmacokinetic Modeling Computing: Multiple Tracer Imaging

Multi-Tracers and Multi-Scans

- Additional dose from multiple CT scans
- Registration problem
- Staff-consuming, time-consuming



- Multiple Tracer in one Scan, technical challenging:
 - Different isotopes emitting positrons of different energy
 - The gamma photons generated by positron annihilation: save energy level (511KeV)
 - Can not be physically differentiated
- Identify the individual tracer based on intrinsic pharmacokinetic differences





Advanced Pharmacokinetic Modeling Computing: Multiple Tracer Imaging

[Cheng et al IEEE Trans Med Imaging 2015]







Parameter Space Reduction

1. Formulate the original multi-tracer model (parameters k) with parameters θ and ν 2.Regularize the model with the measured TAC C_t as prior knowledge

$$\frac{\partial WSSE}{\partial \theta} = \frac{\partial}{\partial \theta} \left\{ \sum_{t=1}^{N_T} \omega_t \left(C_t - \hat{C}_t \right)^2 \right\} = 0$$

3. Results in the representation of \hat{C}_t with ν instead of original parameter k;

Direct image reconstruction

1. EM reconstruction of dynamic PET images

[Cheng, ..., Shi. MICCAI 2013] [Cheng, ..., Shi. PMB 2014]

$$\hat{x}_{jt}^{(n+1)} = \frac{x_t(\mathbf{v}_j^{(n)})}{\sum_i a_{ij}} \sum_i a_{ij} \frac{y_{it}}{\sum_{j'} a_{ij'} x_t(\mathbf{v}_{j'}^{(n)}) + \mathbf{r}_t + \mathbf{s}_t}$$

2. Voxel-wise weighted nonlinear least square fitting (WNLS)

(n)

$$\mathbf{v}_{j}^{(n+1)} = \min_{\mathbf{v}} \sum_{jt} \omega_{jt} (\hat{x}_{jt}^{(n+1)} - x_{t}(\mathbf{v}_{j}^{(n)}))^{2}$$
Nonlinear RPS-Model





Advanced Pharmacokinetic Modeling Computing: Multiple Tracer Imaging

Selected Results









Confounding factor on metabolic signal: age-associated metabolic change

Early diagnosis may be more susceptible to this confounding factor





Semi-Quantitative Analysis: Intensity Normalization for Age Adjustment

Parkinsonism

Atypical parkinsonian syndromes [Goldman & Tanner 1998]

- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Look like Parkinson's Disease (PD) but much more severe
- □ About 20% of PD patients were misdiagnosed
- \Box Diagnostic error \rightarrow wrong treatment

How to differentiate the parkinsonism during the early stages of disease?





Identify best normalization to describe age-related changes Define a quantity for age adjustment





Semi-Quantitative Analysis: Intensity Normalization for Age Adjustment

[Shi et al., SNMMI 2017]





Deutsche Gesellschaft für Nuklearmedizin e.V.

2017

Summer School 2017, 31. August - 2. September 2017



Semi-Quantitative Analysis: Intensity Normalization for Age Adjustment







PSP





0.7

0.6

PD



- Pharmacokinetic modeling
 - Quantitative analysis
 - Less susceptible to confounding factor but more sensitive to noise
 - > Improve the robustness:
 - Linearization
 - Utilization of spatial-temporal consistency: direct parametric image reconstruction, hierarchical modeling
- Intensity normalization
 - Semi-quantitative analysis
 - Easily applicable





TUM NUK Prof. Sibylle Ziegler Prof. Markus Schwaiger PD. Dr. Stefan Förster Dr. Mona Mustafa Dr. Thomas Pyka Dr. Igor Yakushev Mathias Lukas Sybille Reder Dr. Sebastian Fürst Dr. Xiaoyin Cheng Dr. Qian Wang Dr. Zhen Liu

TUM Informatik Prof. Nassir Navab Prof. Bjoern Menze

UCLA Prof. Sung-Cheng Huang

Huashan Hospital, Shanghai Prof. Chuantao Zuo Dr. Ping Wu Prof. Jian Wang





Thank you!

k.shi@tum.de



Deutsche Gesellschaft für Nuklearmedizin e.V.

Summer School 2017, 31. August - 2. September 2017

Page No. 47